dc.contributor
[Udaondo P, García-Delpech S] Department of Ophthalmology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [Hernández C, Briansó-Llort L, Simó-Servat O, Simó R] Grup de Recerca en Diabetis i metabolisme, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Udaondo, Patricia
dc.contributor.author
Hernández Pascual, Cristina
dc.contributor.author
Brianso Llort, Laura
dc.contributor.author
García-Delpech, Salvador
dc.contributor.author
Simó Servat, Olga
dc.contributor.author
Simó Canonge, Rafael
dc.date.accessioned
2025-10-24T08:48:48Z
dc.date.available
2025-10-24T08:48:48Z
dc.date.issued
2020-09-07T11:18:21Z
dc.date.issued
2020-09-07T11:18:21Z
dc.date.issued
2019-11-02
dc.identifier
Udaondo P, Hernández C, Briansó-Llort L, García-Delpech S, Simó-Servat O, Simó R. Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study. J Clin Med. 2019 Nov 2;8(11):1841.
dc.identifier
https://hdl.handle.net/11351/5221
dc.identifier
10.3390/jcm8111841
dc.identifier
000502294400084
dc.identifier.uri
http://hdl.handle.net/11351/5221
dc.description.abstract
Diabetic macular edema; Anti-VEGF agents; Aqueous humor
dc.description.abstract
Edema macular diabético; Agentes anti-VEGF; Humor acuoso
dc.description.abstract
Edema macular diabètic; Agents anti-VEGF; Humor aquós
dc.description.abstract
The objective was to investigate the usefulness of the “liquid biopsy” of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11), and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines, chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders. In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers than rapid responders, but did not reach statistical significance. Finally, those patients who responded to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than patients with rapid response (p = 0.01). In conclusion, “liquid biopsy” of AH could be useful to determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in nature. This approach would allow physicians to select a more rational and cost-effective treatment. Further studies to validate these preliminary results are warranted.
dc.description.abstract
This study was supported by grants from F. Hoffmann-La Roche Ltd. and Instituto de Salud Carlos III (PI16/00541). Laura Brianso is a recipient of a Predoctoral Research Grant from Instituto de Salud Carlos III (FI17/00213).
dc.format
application/pdf
dc.relation
Journal of Clinical Medicine;8(11)
dc.relation
https://www.mdpi.com/2077-0383/8/11/1841
dc.relation
info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00541
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Factors de creixement fibroblàstic
dc.subject
Retinopatia diabètica
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Clinical Laboratory Techniques::Investigative Techniques::Clinical Laboratory Techniques::Specimen Handling::Biopsy::Investigative Techniques::Liquid Biopsy
dc.subject
DISEASES::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Macular Edema
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Angiogenic Proteins::Vascular Endothelial Growth Factors
dc.subject
Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas de laboratorio clínico::técnicas de investigación::técnicas de laboratorio clínico::manejo de muestras::biopsia::técnicas de investigación::biopsia líquida
dc.subject
ENFERMEDADES::oftalmopatías::enfermedades de la retina::degeneración retiniana::degeneración macular::edema macular
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::proteínas angiogénicas::factores de crecimiento endotelial vascular
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores
dc.title
Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
